Biocytogen Announced Completion of New Round of Financing of Multi-Dozen Millions of Dollars to Build R&D Engine for Antibody Drugs
Jun 22, 2021
June 22. Beijing Biocytogen CO., Ltd. ("Biocytogen"), an international biotechnology company conducting new drug research and development based on innovative gene editing model animal technologies, today announced the successful completion of a new round of financing of multi-dozen millions of dollars. This round of financing was jointly completed by Lake Bleu Capital, CPE Yuanfeng, Octagon Capital and OrbiMed.
Biocytogen was established in 2009. With the concept of technology-driven new drug development, Biocytogen continues to increase R&D investment into underlying technology platform of antibody drugs. After more than ten years of development, it has grown from a simple CRO that provides customized gene editing services into an international biotechnology company covering the entire value chain of new drug research and development, including antibody drug target verification, antibody drug discovery, in vivo drug efficacy evaluation, and clinical development.